IOTA Diagnostic Develops M-Strip Device For Cervical Cancer Screening


In a groundbreaking development for women’s health in India, IOTA Diagnostic has received approval from the Central Drugs Standard Control Organization (CDSCO) for its innovative M-Strip device. This device, designed for cervical cancer screening, represents a significant advancement by allowing women to collect samples at home using menstrual blood. This innovation offers unprecedented privacy, convenience, and accessibility, potentially transforming the landscape of cervical cancer screening and early detection.

The M-Strip: A Game-Changer in Women’s Health

The M-Strip device is a pioneering tool in the field of cervical cancer diagnostics. Developed by Dr. Somesh Chandra in collaboration with Sterling Accuris, this device enables women to self-collect samples in the comfort of their homes. The technology utilizes menstrual blood for detecting Human Papillomavirus (HPV) and other infectious diseases, simplifying the screening process and making it less invasive and more accessible.

Key Innovations of the M-Strip

1. At-Home Sample Collection: The M-Strip allows women to collect menstrual blood samples at home, eliminating the need for uncomfortable clinical visits and invasive procedures. This feature addresses privacy concerns and makes the screening process more approachable.

2. Use of Dried Matrix Technology: The device employs a proprietary material that preserves samples for extended periods. This dried matrix technology facilitates easy transportation and storage without the need for cold chain logistics, reducing the complexity and cost of diagnostics.

3. Non-Invasive and User-Friendly Design: Designed with user convenience in mind, the M-Strip is easy to use and does not require the intervention of skilled medical professionals. Women can collect samples within their personal spaces, enhancing their comfort and autonomy.

Impact on Cervical Cancer Screening

Cervical cancer is the second most common cancer among women aged 15-44 in India, with a significant number of new cases and deaths each year. Despite this, only a small percentage of Indian women undergo routine cervical cancer screenings due to societal taboos, lack of awareness, and the invasiveness of current methods. The M-Strip addresses these barriers by providing a discreet and accessible solution.

Advantages Over Traditional Screening Methods

1. Increased Sensitivity: Traditional methods like Pap smears and visual inspections often lack sensitivity in early detection. The M-Strip, by enabling HPV-DNA testing, aligns with the WHO’s recommendations for regular screenings, enhancing the likelihood of early detection and timely intervention.

2. Cost-Effectiveness: By reducing the need for expensive clinical setups and skilled personnel for sample collection, the M-Strip lowers diagnostic costs, making it feasible for women in both urban and remote areas.

3. Promoting Regular Screenings: The ease of use and non-invasive nature of the M-Strip encourage more women to participate in regular screenings, potentially leading to earlier detection and reduced mortality rates.

Supporting Data and Future Prospects

India accounts for nearly 50% of global snakebite deaths, and similar statistics highlight the gravity of cervical cancer. With 123,907 new cases and 77,348 deaths annually, the need for effective and accessible screening methods is paramount. The M-Strip’s ability to facilitate self-sampling and its alignment with WHO guidelines for HPV-DNA testing makes it a crucial tool in combating cervical cancer, particularly in underserved rural areas.

Collaborative Efforts and Recognition

The development and approval of the M-Strip are the results of a collaborative effort by IOTA Diagnostic, The Liana Trust, and notable support from various institutions including BIRAC-DBT, Sristi Innovations, i-Hub Gujarat, and STBI-Vadodara. The device has also received recognition at prominent events such as Global Bio-India 2023, underscoring its potential impact on public health.


The approval of the M-Strip by CDSCO marks a significant milestone in the realm of women’s health and cervical cancer screening in India. By enabling easy, at-home sample collection using menstrual blood, the M-Strip introduces a new era of privacy, convenience, and accessibility in medical diagnostics. This innovation not only aligns with global health recommendations but also paves the way for increased participation in screening programs, ultimately aiming to reduce cervical cancer-related mortality rates across India.

To register for our next masterclass please click here

Melbourne, Australia
(Sat - Thursday)
(10am - 05 pm)